A prospective open‐label trial of a CBD/THC cannabis oil in dravet syndrome

A prospective open‐label trial of a CBD/THC cannabis oil in dravet syndrome

Abstract Introduction Both Δ9 Tetrahydrocannabidiol (THC) and cannabidiol (CBD) components of cannabis, have been shown to have anticonvulsant effects. Cannabis oils are used to treat seizures in drug‐resistant epilepsy (DRE). Recent trials provide data on dosing, side effects, and efficacy of CBD,...

Full description

Bibliographic Details
Main Authors: Bláthnaid McCoy, Laura Wang, Maria Zak, Sameer Al‐Mehmadi, Nadia Kabir, Kenda Alhadid, Kyla McDonald, Grace Zhang, Rohit Sharma, Robyn Whitney, Katia Sinopoli, O. Carter Snead III
Format: Article
Language:English
Published: Wiley 2018-09-01
Series:Annals of Clinical and Translational Neurology
Online Access:https://doi.org/10.1002/acn3.621

Internet

https://doi.org/10.1002/acn3.621

Similar Items